SCM
ALNY icon

Shelton Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Shelton Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.38M Sell
14,556
-281
-2% -$84.8K 0.08% 163
2026
Q1 		$4.91M Sell
14,837
-227
-2% -$77.2K 0.11% 148
2025
Q4 		$5.99M Buy
+15,064
New +$6.67M 0.12% 142

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Shelton Capital Management's ALNY Position: Q2 2026 in Review

Shelton Capital Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 1.9% in Q2 2026, selling an estimated $84.8K and leaving 14,556 shares worth $4.38M. The position accounts for 0.08% of the portfolio, ranked #163.

Shelton Capital Management first reported a position in ALNY in Q4 2025 and has held it in 3 quarters since. The position peaked at $5.99M in Q4 2025. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Shelton Capital Management held 14,556 shares of Alnylam Pharmaceuticals worth $4.38M as of Q2 2026.
  • Shelton Capital Management sold 281 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $84.8K.
  • Alnylam Pharmaceuticals made up 0.08% of Shelton Capital Management's portfolio in Q2 2026, its #163 holding.
  • Shelton Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Shelton Capital Management's Alnylam Pharmaceuticals position peaked at $5.99M in Q4 2025.
  • 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Shelton Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.